Thioctic acid (Synonyms: α-Lipoic Acid; (±)-α-Lipoic acid; DL-α-Lipoic acid)

Name: α-Lipoic Acid
Brand: MedChemExpress
SKU: HY-N0492
Rating: 5.0 (14 reviews)

製品番号: HY-N0492 純度: 99.94%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

α-Lipoic Acid (Thioctic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation. α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells. α-Lipoic Acid can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1077-28-7

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 27	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 27	在庫あり	Estimated Time of Arrival: December 31
Solid
500 mg	$25	在庫あり	Estimated Time of Arrival: December 31
1 g	$35	在庫あり	Estimated Time of Arrival: December 31
5 g	$84	在庫あり	Estimated Time of Arrival: December 31
10 g	$118	在庫あり	Estimated Time of Arrival: December 31
50 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 14 publication(s) in Google Scholar

Other Forms of α-Lipoic Acid:

Lipoic acid 在庫あり
Lipoic acid (Standard) 在庫あり
α-Lipoic Acid-d₅ 在庫あり
α-Lipoic Acid sodium 在庫あり
α-Lipoic Acid (Standard) 在庫あり

顧客検証

In Vivo Efficacy Study

Cell Proliferation/Viability Assay

IHC

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2025 Oct 31;15(1):150. [Abstract]; Response experiments were performed in TGF-β1-induced hEndoSCs using siBlk and ERS activator (α-Lipoic Acid (α-LA)), successively. Detection of the protein expression levels by Western blot. In TGF-β1-induced hEndoSCs, Collagen I and α-SMA expression were downregulated by BLK knockdown using siBLK, and such inhibitory effect was counteracted by the ERS agonist α-Lipoic Acid (α-LA, 100 μM; 24 h).

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Cell Biosci. 2025 Oct 31;15(1):150. [Abstract]; Immunofluorescence detected the effect of intervention ERS on the expression of Collagen I (red) and α-SMA (green), respectively. DAPI (blue) was used to stain nuclei. The results showed that the ERS agonist α-Lipoic Acid (α-LA, 100 μM; 24 h) further upregulated the expression of Collagen I and α-SMA induced by TGF-β1.

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2025 Sep;33(9):5563-5581. [Abstract]; The macroscopic appearance and macroscopic scores of colon tissues were evaluated in all groups. Compared with the C group, the colon tissue damage characterized by ulceration, hyperemia and mucosal edema was significantly increased in the UC group, M group (50 mg/kg; oral gavage; once daily for 14 days; rats) and α-lipoic acid (ALA) group (100 mg/kg; oral gavage; once daily for 14 days; rats) (p < 0.01). The macroscopic score was lower in the M + ALA group than in other colitis-induced groups, although the difference was not statistically significant (*p* > 0.05).

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Apr 14:155:114539. [Abstract]; SH-SY5Y cell viability reached 80% with α-Lipoic Acid (α-ALA) pretreatment at 150 μmol/L for 8 h.

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Apr 14:155:114539. [Abstract]; TH and α-Synuclein Expression Analysis: The expression of TH in the brains of the 6-OHDA group decreased, while both α-Lipoic Acid (α-ALA, 40 mg/kg; i.p.; once daily for 14 days) pretreatment and treatment significantly improved TH expression. In contrast, the expression of α-synuclein in the brains of the 6-OHDA group increased. α-ALA treatment alleviated this change, but α-ALA pretreatment did not show improvement.

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Apr 14:155:114539. [Abstract]; In the open field test, 6-OHDA reduced the movement distance, and both α-Lipoic Acid (α-ALA, 40 mg/kg; i.p.; once daily for 14 days; C57BL/6 mice) pretreatment and α-ALA treatment ameliorated this effect (n = 9–10).

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Apr 14:155:114539. [Abstract]; TH expression decreased in the 6-OHDA group, but increased in both the α-Lipoic Acid (α-ALA, 40 mg/kg; i.p.; once daily for 14 days; C57BL/6 mice) + 6-OHDA and 6-OHDA+α-ALA groups.

: α-Lipoic Acid purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Apr 14:155:114539. [Abstract]; α-Lipoic Acid (α-ALA, 40 mg/kg; i.p.; once daily for 14 days) pretreatment and treatment alleviated the upregulation of S100A9 protein expression induced by 6-OHDA in C57BL/6 mice, as validated by immunofluorescence analysis.

NF-κB アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

HIV アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

HIV HIV-1 HIV-2

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Human Endogenous Metabolite Microbial Metabolite

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

α-Lipoic Acid (Thioctic acid) is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid inhibits NF-κB-dependent HIV-1 LTR activation^[1]^[2]^[3]. α-Lipoic Acid induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells^[4]. α-Lipoic Acid can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1^[5].

IC₅₀ & Target^[1]^[2]

Human Endogenous Metabolite

NF-κB

Mitochondrial bioenergetics

HIV-1

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
A549	IC₅₀	>50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
A549	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
Bel-7402	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
Bel-7402	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
Bel-7402	IC₅₀	>50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
K562	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
K562	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
K562	IC₅₀	>50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
L02	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
L02	IC₅₀	>50 3 Compound: alpha-thioctic acid	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
L02	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
PBMC	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
PBMC	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
PBMC	IC₅₀	>50 3 Compound: alpha-thioctic acid	Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PBMC assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
SGC-7901	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
SGC-7901	IC₅₀	>50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]
SGC-7901	IC₅₀	> 50 3 Compound: alpha-thioctic acid	Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human SGC7901 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31202992]

体外実験

The long terminal repeat (LTR) of HIV-1 is the target of cellular transcription factors such as NF-κB, and serves as the promoter-enhancer for the viral genome when integrated in host DNA^[1]. α-Lipoic Acid (Alpha-Lipoic acid, ALA), a naturally occurring dithiol compound, plays an essential role in mitochondrial bioenergetics. α-Lipoic Acid reduces lipid accumulation in the liver by regulating the transcriptional factors SREBP-1, FoxO1, and Nrf2, and their downstream lipogenic targets via the activation of the SIRT1/LKB1/AMPK pathway. Treatment of cells with α-Lipoic Acid (250, 500 and 1000 μM) significantly increases the NAD⁺/NADH ratio in HepG2 cells (P<0.05 or P<0.01). Treatment with α-Lipoic Acid (50, 125, 250 and 500 μM) increases SIRT1 activity in HepG2 cells. α-Lipoic Acid (50, 125, 250, 500 and 1000 μM) increases phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) in HepG2 cells in a dose-dependent fashion^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

C57BL/6J mice, divided into four groups, are fed an high-fat diet (HFD) for 24 weeks to induce nonalcoholic fatty liver disease (NAFLD) followed by daily administration of α-Lipoic Acid. Then, the effects of α-Lipoic Acid on hepatic lipid accumulation in long-term HFD-fed mice are assessed. Administration of α-Lipoic Acid (100 mg/kg or 200 mg/kg) markedly reduces visceral fat mass in mice. In addition, α-Lipoic Acid (100 mg/kg or 200 mg/kg) treatment inhibits the appetite and causes a dramatic weight loss (all P<0.05)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

分子量

206.33

分子式

C₈H₁₄O₂S₂

CAS 番号

1077-28-7

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(O)CCCCC1SSCC1

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Endogenous metabolite

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (484.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.8466 mL	24.2330 mL	48.4660 mL
5 mM	0.9693 mL	4.8466 mL	9.6932 mL
10 mM	0.4847 mL	2.4233 mL	4.8466 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (48.47 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.94%

Select Batch:

データシート (278 KB) SDS (597 KB)

COA (244 KB) HNMR (118 KB) RP-HPLC (213 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Xiao L, et al. Activity of the dietary antioxidant ergothioneine in a virus gene-based assay for inhibitors of HIV transcription. Biofactors. 2006;27(1-4):157-65. [Content Brief]

[2]. Lei D, et al. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. Oncotarget. 2018 Jan 30;9(15):12137-12153. [Content Brief]

[3]. Yang Y, et al. Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J Nutr Biochem. 2014 Nov;25(11):1207-1217. [Content Brief]

[4]. Pibiri M, et al. α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells. Sci Rep. 2020 Apr 28;10(1):7139. [Content Brief]

[5]. Liu J, et al. Nanoaggregates of Disulfide-Decorated TrxR Inhibitor Promote Cellular Uptake, Selective Targeting, and Antitumor Efficacy. Langmuir, 2022.

細胞実験 ^[1]	The human hepatocellular carcinoma (HepG2) cell line is cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37°C and 5% CO₂. HepG2 cells are treated with AMPK inhibitor (CC, 20 μM, 0.5 h), SIRT1 inhibitor (NA, 10 mM, 12 or 24 h), and AMPK activator (AICAR, 2 mM, 1 h), Palmitate (PA, 125 μM, 12 h) and α-Lipoic Acid (250 μM, 6 or 12 h)^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[1]	Mice^[1] Male C57BL/6J mice (6-week-old; body weight: 22-24 g) are allowed ad libitum access to normal diet and water for 2 weeks before dividing into four groups (n=8): normal diet (ND) (10% energy from fat), high-fat diet (HFD) (60% energy from fat) and HFD plus α-Lipoic Acid (100 mg/kg or 200 mg/kg). After 24 weeks of treatment, blood samples are collected after the eyeballs of the mice are extracted for serum preparation by centrifugation at 2000×g for 10 min at 4°C. The liver tissues are harvested in liquid nitrogen and stored at -80°C. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Xiao L, et al. Activity of the dietary antioxidant ergothioneine in a virus gene-based assay for inhibitors of HIV transcription. Biofactors. 2006;27(1-4):157-65. [Content Brief] [2]. Lei D, et al. Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. Oncotarget. 2018 Jan 30;9(15):12137-12153. [Content Brief] [3]. Yang Y, et al. Alpha-lipoic acid improves high-fat diet-induced hepatic steatosis by modulating the transcription factors SREBP-1, FoxO1 and Nrf2 via the SIRT1/LKB1/AMPK pathway. J Nutr Biochem. 2014 Nov;25(11):1207-1217. [Content Brief] [4]. Pibiri M, et al. α-Lipoic acid induces Endoplasmic Reticulum stress-mediated apoptosis in hepatoma cells. Sci Rep. 2020 Apr 28;10(1):7139. [Content Brief] [5]. Liu J, et al. Nanoaggregates of Disulfide-Decorated TrxR Inhibitor Promote Cellular Uptake, Selective Targeting, and Antitumor Efficacy. Langmuir, 2022.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.8466 mL	24.2330 mL	48.4660 mL	121.1651 mL
	5 mM	0.9693 mL	4.8466 mL	9.6932 mL	24.2330 mL
	10 mM	0.4847 mL	2.4233 mL	4.8466 mL	12.1165 mL
	15 mM	0.3231 mL	1.6155 mL	3.2311 mL	8.0777 mL
	20 mM	0.2423 mL	1.2117 mL	2.4233 mL	6.0583 mL
	25 mM	0.1939 mL	0.9693 mL	1.9386 mL	4.8466 mL
	30 mM	0.1616 mL	0.8078 mL	1.6155 mL	4.0388 mL
	40 mM	0.1212 mL	0.6058 mL	1.2117 mL	3.0291 mL
	50 mM	0.0969 mL	0.4847 mL	0.9693 mL	2.4233 mL
	60 mM	0.0808 mL	0.4039 mL	0.8078 mL	2.0194 mL
	80 mM	0.0606 mL	0.3029 mL	0.6058 mL	1.5146 mL
	100 mM	0.0485 mL	0.2423 mL	0.4847 mL	1.2117 mL

α-Lipoic Acid Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Thioctic acid (Synonyms: α-Lipoic Acid; (±)-α-Lipoic acid; DL-α-Lipoic acid)

カスタマーレビュー

Other Forms of α-Lipoic Acid:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

NF-κB アイソフォーム固有の製品をすべて表示:

HIV アイソフォーム固有の製品をすべて表示:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

α-Lipoic Acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Thioctic acid (Synonyms: α-Lipoic Acid; (±)-α-Lipoic acid; DL-α-Lipoic acid)

カスタマーレビュー

Other Forms of α-Lipoic Acid:

Thioctic acid 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

NF-κB アイソフォーム固有の製品をすべて表示:

HIV アイソフォーム固有の製品をすべて表示:

Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Thioctic acid 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

α-Lipoic Acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report